Study Backs RSV Vaccine Safety During Pregnancy

The study, published on July 8 in JAMA Network Open, adds real-world evidence to the existing data from clinical trials about the safety of Pfizer’s Abrysvo vaccine. The researchers found that there wasn’t a significant statistical difference in preterm birth rates between vaccinated women (5.9 percent) and unvaccinated women (6.7 percent). 

“The real-world evidence provides an additional layer of confidence about the safety of this vaccine during pregnancy,” said the study’s lead author Dr. Moeun Son, associate professor of obstetrics and gynecology at Weill Cornell Medicine. “Randomized clinical trials don’t always emulate the populations we see in the clinical setting, but now we have data from multiple populations showing no increase in preterm birth risk.”

The study’s senior author is Dr. Heather Lipkind, professor of obstetrics and gynecology and director of Clinical Maternal-Fetal Medicine at Weill Cornell Medicine.

Read the full story here.